In addition to these methodological enhancements and replication of previous studies, our findings also demonstrate that therapies that seek to modify HDL or apolipoprotein A-I [68] will only have beneficial effects if they also lower apolipoprotein B. Their influence on apolipoprotein B is likely to account for any effects of therapies aimed at increasing HDL cholesterol or apolipoprotein A-I on the risk of CHD [66]. The gene discussed is APOB; the disease is coronary artery disorder.